PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY PRODUCT • Market segmentation by product • Comparison by product • Retinal disorder therapeutics - Market size and forecast 2018-2023 • Glaucoma therapeutics - Market size and forecast 2018-2023 • Dry eye syndrome therapeutics - Market size and forecast 2018-2023 • Eye infections and inflammation therapeutics - Market size • and forecast 2018-2023 • Other therapeutics - Market size and forecast 2018-2023 • Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Market trends PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • ALLERGAN • F. Hoffmann-La Roche Ltd • Novartis AG • Regeneron Pharmaceuticals, Inc. • Santen Pharmaceutical Co., Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations PART 15: EXPLORE TECHNAVIO   Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Product - Market share 2018-2023 (%) Exhibit 18: Comparison by product Exhibit 19: Retinal disorder therapeutics - Market size and forecast 2018-2023 ($ millions) Exhibit 20: Retinal disorder therapeutics - Year-over-year growth 2019-2023 (%) Exhibit 21: Glaucoma therapeutics - Market size and forecast 2018-2023 ($ millions) Exhibit 22: Glaucoma therapeutics - Year-over-year growth 2019-2023 (%) Exhibit 23: Dry eye syndrome therapeutics - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Dry eye syndrome therapeutics - Year-over-year growth 2019-2023 (%) Exhibit 25: Eye infections and inflammation therapeutics - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Eye infections and inflammation therapeutics - Year-over-year growth 2019-2023 (%) Exhibit 27: Other therapeutics - Market size and forecast 2018-2023 ($ millions) Exhibit 28: Other therapeutics - Year-over-year growth 2019-2023 (%) Exhibit 29: Market opportunity by product Exhibit 30: Customer landscape Exhibit 31: Market share by geography 2018-2023 (%) Exhibit 32: Geographic comparison Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 34: North America - Year-over-year growth 2019-2023 (%) Exhibit 35: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 36: Europe - Year-over-year growth 2019-2023 (%) Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Asia - Year-over-year growth 2019-2023 (%) Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 40: ROW - Year-over-year growth 2019-2023 (%) Exhibit 41: Key leading countries Exhibit 42: Market opportunity Exhibit 43: Late-stage pipeline drugs Exhibit 44: Patent expiry Exhibit 45: Impact of drivers and challenges Exhibit 46: Mergers and acquisitions in 2017 and 2018 Exhibit 47: Gene therapies under development Exhibit 48: Vendor landscape Exhibit 49: Landscape disruption Exhibit 50: Vendors covered Exhibit 51: Vendor classification Exhibit 52: Market positioning of vendors Exhibit 53: ALLERGAN - Vendor overview Exhibit 54: ALLERGAN - Business segments Exhibit 55: ALLERGAN - Organizational developments Exhibit 56: ALLERGAN - Geographic focus Exhibit 57: ALLERGAN - Segment focus Exhibit 58: ALLERGAN - Key offerings Exhibit 59: F. Hoffmann-La Roche Ltd - Vendor overview Exhibit 60: F. Hoffmann-La Roche Ltd - Business segments Exhibit 61: F. Hoffmann-La Roche Ltd - Organizational developments Exhibit 62: F. Hoffmann-La Roche Ltd - Geographic focus Exhibit 63: F. Hoffmann-La Roche Ltd - Segment focus Exhibit 64: F. Hoffmann-La Roche Ltd - Key offerings Exhibit 65: Novartis AG - Vendor overview Exhibit 66: Novartis AG - Business segments Exhibit 67: Novartis AG - Organizational developments Exhibit 68: Novartis AG - Geographic focus Exhibit 69: Novartis AG - Segment focus Exhibit 70: Novartis AG - Key offerings Exhibit 71: Regeneron Pharmaceuticals, Inc. - Vendor overview Exhibit 72: Regeneron Pharmaceuticals, Inc. - Business segments Exhibit 73: Regeneron Pharmaceuticals, Inc. - Organizational developments Exhibit 74: Regeneron Pharmaceuticals, Inc. - Key offerings Exhibit 75: Santen Pharmaceutical Co., Ltd. - Vendor overview Exhibit 76: Santen Pharmaceutical Co., Ltd. - Business segments Exhibit 77: Santen Pharmaceutical Co., Ltd. - Organizational developments Exhibit 78: Santen Pharmaceutical Co., Ltd. - Geographic focus Exhibit 79: Santen Pharmaceutical Co., Ltd. - Key offerings Exhibit 80: Validation techniques employed for market sizing

ALLERGAN, F. Hoffmann-La Roche Ltd Novartis AG Regeneron Pharmaceuticals Inc Santen Pharmaceutical Co., Ltd.